NOX-E36 (emapticap pegol) is a Spiegelmer* that binds and neutralizes the human chemokine CCL2, also referred to as MCP-1 (C-C Chemokine Ligand 2 / Monocyte Chemoattractant Protein 1), and related chemokines, aimed at the treatment of complications arising from diabetic nephropathy. Based on pre-clinical stage work it is believed that the neutralization of this chemokine will prevent infiltration of pro-inflammatory cells into the kidney, thereby allowing existing inflammation to resolve over time. The expected downstream effects include preservation of podocyte numbers, as well as conservation of renal structure and function.
NOX-E36 has completed a Phase 2a exploratory study which included 76 patients with Type 2 diabetes and proteinuria on top of standard of care. NOXXON believes promising results were obtained on two key parameters: protein in the urine as measured by the albumin to creatinine ratio (ACR), and glycated hemoglobin (HbA1c) in blood. Based on the results observed, NOXXON believes NOX-E36 may be the first disease-modifying drug for this indication. NOX-E36 was generally well tolerated in this study.
About the target
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. Both CCL2 and its receptor CCR2 have been demonstrated to be induced and involved in a variety of inflammatory diseases.